Trial Profile
A Retrospective study to evaluate the safety and efficacy of the PrOD regiment (Paritaprevir/Ritonavir/Ombitasvir Plus Dasabuvir) and their drug-drug interactions in HCV Genotype 1 patients with Chronic Kidney Disease
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 30 Nov 2018
Price :
$35
*
At a glance
- Drugs Dasabuvir (Primary) ; Ombitasvir/paritaprevir/ritonavir (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- 30 Nov 2018 New trial record